Supporting Market Access & ReimbursementWe offer support to achieve optimal
We offer support to achieve optimal
market access of pharmaceuticals
Advice
Advice on market access strategy
Compilation
Compilation of the (country-specific) reimbursement dossier
Development of risk sharing procedures
Development of risk sharing procedures and conditional reimbursement schemes (managed entry schemes)
Coordination and monitoring
Coordination and monitoring of applied reimbursement procedures and assessment of effectiveness of reimbursement measures. (includes the analysis of the pharmaceutical and health care costs and estimations of event impact)
Feasibility analyses
•Feasibility analyses
• product characteristics
• product development
• the local market access environment (which recognises comparators, target population and value requirements), …
• product characteristics
• product development
• the local market access environment (which recognises comparators, target population and value requirements), …
Description of reimbursement
Description of reimbursement options and links to product reimbursement modalities
Mapping of a stakeholder environment
Mapping of a stakeholder environment (insurance companies, academia, members of the medical and pharmaceutical communities…)
Involvement at hearings
Involvement at hearings in line with the recommendations of the reimbursement committee
Organisation of Delphi panels
Organisation of Delphi panels to obtain input for budget-impact analysis and cost-effectiveness models
Relative effectiveness assessments
Relative effectiveness assessments and health technology assessments – incorporating EUnetHTA recommendations
Integration of relative effectiveness elements
Integration of relative effectiveness elements in the clinical development plan